Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17763832 | 1.00 | PDE2A (0.44) | PDE2AL3MBTL1RAB9AALOX5APFEN1 | |
| SCHEMBL26101015 | 0.86 | L3MBTL1 (0.46) | PDE2AL3MBTL1RAB9ACASRHTR2A | |
| SCHEMBL13698776 | 0.86 | PDE2A (0.46) | PDE2AL3MBTL1RAB9AALOX5APFEN1 | |
| SCHEMBL29472437 | 0.83 | PDE2A (0.60) | PDE2AL3MBTL1RAB9AALOX5APFEN1 | |
| SCHEMBL18103190 | 0.83 | PDE2A (0.44) | PDE2AL3MBTL1RAB9AALOX5APFEN1 | |
| SCHEMBL22279132 | 0.83 | PDE2A (0.60) | PDE2AL3MBTL1RAB9AALOX5APFEN1 | |
| SCHEMBL22221150 | 0.81 | L3MBTL1 (0.42) | PDE2AL3MBTL1RAB9AALOX5APFEN1 | |
| SCHEMBL24653027 | 0.80 | PDE2A (0.46) | PDE2AL3MBTL1RAB9AALOX5APFEN1 | |
| SCHEMBL22221151 | 0.80 | PDE2A (0.46) | PDE2AL3MBTL1RAB9AALOX5APFEN1 | |
| Hydrochloric Acid SCHEMBL31137630 | 0.79 | HTR2A (0.50) | PDE2AL3MBTL1RAB9ACASRHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098159-A1 | CARBAMATE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098159-A1 | CARBAMATE DERIVATIVES AND USES THEREOF | CASP1, IL1B, PYCARD | PDE2A 900/4885L3MBTL1 4057/4885RAB9A 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.